Haemonetics HAE · NYSE
$118.76 +0.41% (+$0.48)
Summary
61 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 58% a year over the last 3 years.
- Out of every 100 USD of revenue, 22 USD is left as free cash.
- It bought back its own shares for $225.0M in the last fiscal year, 4.2% of its market value.
What to watch
- The share price is above the Bulios Fair Price.
- Repaying its net debt would take 3.6 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 55.9 USD for 1 USD of yearly profit. Over the last five years it was 48.0 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.6% a year over 5 years. Over the last 3 years it grew by 11% a year. For the next fiscal year analysts expect revenue to fall by 2.6%. Earnings per share grew by 58% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 43 USD
- Research and development 4.4 USD
- Sales and administration 35 USD
- Taxes and other 11 USD
- Net profit 7.1 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 7.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 4.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 12
- Hold 9
- Sell 0
Today's price within the analysts' price targets
The average target of $130.8 is 10% above today's price. 57% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- Hospital 27%
- Plasma 24%
- Hemostasis Management, Hospital 17%
- Interventional Technologies, Hospital 11%
- Blood Center 10%
- Other 10%
By region
- UNITED STATES 74%
- Europe 14%
- Asia 6.5%
- JAPAN 5.1%
- Other Country or Region 0.9%
Hospital brings in 27% of revenue.
Segments in detail